EC Number   |
Protein Variants |
Reference |
|---|
   3.4.22.B50 | A67Y |
the mutation enhances the catalytic efficiency of the enzyme about 8fold while the thermostability of the mutant enzyme remains unchanged. The specific activity against azo-casein is almost 2.4 times higher than wild type |
732725 |
| 3.4.22.B50 | C106A |
inactive |
718275 |
| 3.4.22.B50 | C112S |
site-directed mutagenesis, active site cysteine mutant, forms a noncovalent complex with ubiquitin, crystal structure analysis |
731149 |
| 3.4.22.B50 | C112S |
site-directed mutagenesis, the C112S mutant is monomeric, ubiquitin binding crystal structure analysis, overview |
731069 |
| 3.4.22.B50 | C1651A |
Plpro active-site mutant |
-, 670085 |
| 3.4.22.B50 | C1651A |
purified SARS-CoV PLpro protein containing an alanine substitution at putative catalytic residues |
-, 670084 |
| 3.4.22.B50 | C1729A |
the mutant shows reduced interferon antagonistic activity compared to that of the wild type enzyme |
732257 |
| 3.4.22.B50 | C1732A |
encodes a substitution of a cysteine residue, predicted to be critical for zinc binding |
-, 670084 |
| 3.4.22.B50 | C270A/H332A |
active site mutant |
732827 |
| 3.4.22.B50 | D165A |
site-directed mutagenesis, the mutant shows reduced activity in deubiquitination compared to the wild-type enzyme |
731069 |
